Key result
Ischemic modified albumin levels were significantly elevated in COVID-19 positive patients with acute cardiac injury compared to healthy controls (174.70 vs 57.42), serving as a potential early biomarker.
Why the study?
Coronavirus disease 2019 prognosis is linked to cardiac problems, prompting evaluation of ischemic modified albumin levels to aid early diagnosis and treatment of cardiac complications.
Are ischemic modified albumin levels elevated in patients with acute cardiac injury with or without COVID-19 compared to healthy volunteers?
Observational (n=176)
No
Are ischemic modified albumin levels elevated in patients with acute cardiac injury with or without COVID-19 compared to healthy volunteers?
Absolute Event Rate: 174.7% vs 57.42%
p-value: p=<0.001
Ischemic modified albumin levels are elevated in patients with acute cardiac injury regardless of COVID-19 status, suggesting it may be a useful biomarker for evaluating cardiac injury in these patients.
Elevated IMA associates with acute cardiac injury in COVID-19; hypothesis-generating for biomarker use and requires prospective validation.
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 is the source of the global pandemic known as coronavirus disease 2019, and the disease prognosis is also linked to the prevalence of cardiac problems. In our study, we aimed to contribute to the early diagnosis and treatment of cardiac complications by evaluating ischemic modified albumin levels in adults with coronavirus disease 2019 disease. METHODS: Our study was conducted with a total of 176 cases: group 1 (n = 70) with cardiac injury and coronavirus disease 2019 (+), group 2 (n = 57) with cardiac injury and coronavirus disease (-), and group 3 (n = 49) with healthy volunteers. The Mann-Whitney U test, the average, SD, minimum and maximum values, intergroup comparison of the results, and statistical significance were evaluated with the Pearson correlation coefficient. RESULTS: As a result of the bilateral comparisons, ischemic modified albumin measurements of the coronavirus disease 2019 (+) and coronavirus disease 2019 (-) groups were higher than the control group (P =.006 and P =.006, respectively). There was no statistically significant difference between ischemic modified albumin measurements of coronavirus disease 2019 (+) and coronavirus disease 2019 (-) groups. CONCLUSION: Ischemic modified albumin measurement accelerates the diagnosis and treatment process in the evaluation of cardiac injuries in coronavirus disease 2019 patients.
No takes yet. Share an insight, caveat, or question.
Seyhan Ördekçi (2023) conducted an observational in Acute cardiac injury and COVID-19 (n=176). COVID-19 infection with acute cardiac injury vs. Healthy volunteers was evaluated on Ischemic modified albumin (IMA) levels (p=<0.001). Ischemic modified albumin levels were significantly elevated in COVID-19 positive patients with acute cardiac injury compared to healthy controls (174.70 vs 57.42), serving as a potential early biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: